Clinical trial

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Recruiting now · Not applicable · 1 countries · Registry ID NCT05419726

Recruiting nowNot applicableObservational

What this study is about

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersAccepted

ConditionObesity

Full registry criteria

Inclusion Criteria: * Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study) * \>18 years of age and willing to participate * Male or post-menopausal females Exclusion Criteria: * History of prior neck surgery and /or neck irradiation * Use of beta blocker agents * Use of any other glucose lowering medication * History of neuropathic disorders (e.g. diabetic neuropathy) * Diabetic patients * Individuals without normal thyroid function * Individuals with cancer * Any significant chronic disease or renal, hepatic or endocrine disease * Current smokers * Inability of patient to provide consent either for medical reasons or psychiatric reasons

Treatments and study arms

Semaglutide Injectable Product (not provided by the study)

Drug

Study Procedure: Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall.

Primary outcomes

change in supraclavicular temperature with cold exposure20weeks

delta temperature

change in caloric intake20weeks

caloric intake

basal metabolic rate20 weeks

basal metabolic rate (ml O2/min or joule per hour per kg body mass)

Study locations

1 locations were listed when this page was built. The first 40 are shown.

UCLA Health🇺🇸 Los Angeles, California, United States

Open map

Julie Sorg, MSNContact